Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) 
inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes 
mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been 
justified by the fact that its mechanism of action is independent of insulin 
secretion or action. However, some serious side effects, including severe anion 
gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been 
reported. Prompt identification of the causal association and initiation of 
appropriate therapy should be instituted for this life threatening condition.